Washington, D.C. 20549 





Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 17, 2017 (October 2, 2017) 


The ExOne Company

(Exact name of registrant as specified in its charter) 













(State or other jurisdiction 
of incorporation)


(Commission File Number)


(IRS Employer Identification No.)





127 Industry Boulevard 
North Huntingdon, Pennsylvania



(Address of principal executive offices)


(Zip Code)

Registrant’s telephone number, including area code: (724) 863-9663

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    





Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers


(b)On Tuesday, October 17, 2017, the Board of Directors of The ExOne Company (the “Company”) accepted the resignation of Dr. Raymond J. Kilmer.  Also on October 17, 2017, the Compensation Committee of the Board of Directors of the Company approved a modification of the restricted stock award granted to Dr. Kilmer on February 10, 2017, resulting in an acceleration of vesting of an approximate pro rata amount of 4,000 shares of the 5,000 shares that otherwise would have vested on February 10, 2018.



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.











The ExOne Company









October 20, 2017









Loretta L. Benec

General Counsel